Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  capecitabine
Find trials that include:  Any drugs shown
Results 1-25 of 60 for your search:
Start Over
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NL36315.042.11, NCI-2014-01600, 2010-023957-12, NCT01558921
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-362, NCI-2014-01324, NCT02117479
A Study of Ruxolitinib in Pancreatic Cancer Patients
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-363, NCI-2014-01487, NCT02119663
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15372, NCI-2015-00221, 2014-002240-40, I4T-MC-JVCU, NCT02314117
Capecitabine and Vorinostat in Treating Patients With Advanced or Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0803003591, NCI-2012-00151, NCT00719875
Combination Chemotherapy Followed by Radiation Therapy, Carboplatin, and Everolimus in Treating Patients with Esophageal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CRAD001CUS159T, NCI-2012-00166, WCI1871-10, NCT01490749
Capecitabine and Ziv-Aflibercept in Treating Patients with Refractory Solid Tumors or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00037688, NCI-2013-00472, NCT01661972
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Cyclodextrin-Based Polymer-Camptothecin CRLX10, Capecitabine, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1315, NCI-2014-00897, NCT02010567
Gemcitabine Hydrochloride, Docetaxel, Capecitabine, Cisplatin, and Irinotecan Hydrochloride in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: J14161, NCI-2015-00235, NCT02324543
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
Lapatinib Ditosylate and Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-437, NCI-2013-00670, NCT00881621
Gemcitabine Hydrochloride, Docetaxel, and Capecitabine in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: AAAB4460, NCI-2011-00695, NCT00882310
Hydroxychloroquine, Bevacizumab, and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 070806, NCI-2012-00527, CINJ-070806, NCT01006369
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 15309, NCI-2009-01492, NCT01044433
Capecitabine, Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Stage II-III Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAD6491, NCI-2010-00829, NCT01065870
Panitumumab in Treating Patients with Locally Advanced or Metastatic Small Intestine or Ampulla of Vater Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0458, NCI-2012-01894, NCI-2010-02085, NCT01202409
Proton or Photon Beam Radiation Therapy, Capecitabine, and Hydroxychloroquine in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-073, NCI-2012-00148, NCT01494155
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Start Over